Conference Room 3010, Jan Mouton Learning Centre, Stellenbosch University
Stellenbosch University, in partnership with the Stellenbosch Institute for Advanced Study (STIAS), cordially invites you to a Public Lecture by Dr Clifton E. Barry III as part of the Nobel Symposium in 'Chemistry on Tuberculosis and antibiotic resistance: From basic drug discovery to clinic'. Dr Barry is chief of the Tuberculosis Research Section in the Laboratory of Clinical Infectious Diseases at the National Institute of Allergy and Infectious Diseases (NIAID) in the USA.
This is the second time that the Nobel Symposia activities are coming to Africa.
Please join us for a cocktail after the lecture - RSVP at https://forms.office.com/r/6vTUkQ8cqS
More about the lecture: A chemist's eye on the future of Tuberculosis chemotherapy
Standard tuberculosis chemotherapy is far too lengthy to achieve the goals expressed at the second United Nations General Assembly High-Level Meeting on Tuberculosis recently. Achieving a shorter duration of treatment requires unprecedented innovation across multiple disciplines and a much more detailed understanding of human clinical disease. In this lecture I will describe studies we have undertaken in the Western Cape and China to provide a basis for understanding the pathophysiology of human disease and more rapidly identifying combination therapies that will lead to significant treatment shortening. Both pre-clinically and clinically we are in the middle of a “Golden Age" of tuberculosis research that, if successful, may allow us to achieve our shared goals of ending tuberculosis by 2030.
More about the speaker
Dr. Clifton E. Barry III received his Ph.D. in organic and bio-organic chemistry in 1989 from Cornell University, studying the biosynthesis of complex natural products. Following postdoctoral research in the chemistry department at Johns Hopkins University (1989 to 1992), Dr. Barry joined the Intramural Research Program of the National Institute of Allergy and Infectious Diseases' (NIAID's) Rocky Mountain Laboratories in Hamilton, Montana. In 1998, he was tenured as chief of the Tuberculosis Research Section (TRS) in the Laboratory of Clinical Infectious Diseases of NIAID.
The TRS is a multidisciplinary group of research scientists comprised of biologists, chemists and clinicians who share a common focus on TB. TRS projects focus on understanding the scientific issues that facilitate the development of drugs that will make a genuine difference in the outcome for TB patients globally. TRS scientists are highly interactive worldwide in this endeavor and as a result of our outstanding collaborations TRS is the most highly cited TB research group in the world according to Thomson Reuters. Dr Barry has authored over 300 publications in the scientific literature. Working with scientists at PathoGenesis in Seattle, TRS played a key role in the preclinical development program that led to PA-824 (Pretomanid, recently approved for treating drug resistant TB). TRS scientists conceived and conducted the Phase 2 clinical trial showing the utility of using linezolid for the treatment of patients suffering from extensively drug-resistant tuberculosis now recommended by WHO.
In addition to TRS laboratories in Bethesda TRS works closely with colleagues at Stellenbosch University (SUN) and the University of Cape Town (UCT) in South Africa. Dr. Barry holds honorary appointments at both UCT and SUN and has a laboratory in the Institute for Infectious Disease and Molecular Medicine at UCT.